Sriveda Boyalakuntla, Riten Kumar
Dec 14, 2025, 12:56
Mentored by Riten Kumar, Sriveda Boyalakuntla Presents Key Research on Infection-Associated Thrombosis at ASH25
Kishore Boyalakuntla, GM and CPO at Re:Build Cadonix, reposted Riten Kumar’s post on LinkedIn:
“Congrats Sriveda Boyalakuntla on the work related to infection associated thrombosis. It is special to be mentored by Riten Kumar and the team at Boston Children’s Hospital.”
Quoting Riten Kumar’s post:
“Last day at ASH25 – interesting subgroup analysis from the RENOVE trial, increased CRNM bleeding with apixaban and aspirin, but not NSAIDs and Sriveda BoyalaKuntla’s excellent presentation on infection associated thrombosis, finished off with trainees – past, present and future!”
Get the latest on Hemostasis Today.
-
Jun 26, 2026, 18:28Daniel Pereira Monteiro: Why Is Beta Thalassaemia Major so Severe?
-
Jun 26, 2026, 18:27Pradip Pawar: Cell and Gene Therapy – Transforming Medicine in the 21st Century
-
Jun 26, 2026, 18:26Aviva Schwartz: How Can We Better Protect Patients After an Ischemic Stroke?
-
Jun 26, 2026, 18:25Does Reversing Factor Xa Inhibitors Really Carry as Much Thrombotic Risk as We Think? – RPTH Journal
-
Jun 26, 2026, 18:25Akshat Jain: Novel Therapies in Childhood Blood and Cancer Disorders
-
Jun 26, 2026, 16:57Abdul Muqtadir Abbasi: Anticoagulation in DVT Patients With Hidden Varices Requires Extreme Caution
-
Jun 26, 2026, 16:42Anesa Mulabecirovic: Why Von Willebrand Disease Takes Years to Diagnose in Women
-
Jun 26, 2026, 16:32Kaitlin Lichty: A New Identity Reflecting a Shared Legacy of Bleeding Disorders
-
Jun 26, 2026, 16:07Toong Youttananukorn: The WFH Registry Driving Better Care and Advocacy